Literature DB >> 485611

Specific active immunotherapy for melanoma.

H F Seigler, E Cox, F Mutzner, L Shepherd, E Nicholson, W W Shingleton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 485611      PMCID： PMC1344672          DOI： 10.1097/00000658-197909000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  5 in total

1.  The significance of humoral antibodies in the localization of human malignant melanoma.

Authors:  M G Lewis; E McCloy; J Blake
Journal:  Br J Surg       Date:  1973-06       Impact factor: 6.939

2.  Clinical and immunological significance of human melanoma cytotoxic antibody.

Authors:  A J Bodurtha; D O Chee; J F Laucius; M J Mastrangelo; R T Prehn
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

3.  HLA restriction of non-HLA--A, --B, --C and --D cell mediated lympholysis (CML).

Authors:  E Goulmy; A Termijtelen; B A Bradley; J J van Rood
Journal:  Tissue Antigens       Date:  1976-11

4.  Study of antibodies against human melanoma produced by somatic cell hybrids.

Authors:  H Koprowski; Z Steplewski; D Herlyn; M Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

5.  Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation.

Authors:  R J Winchester; G D Ross; C I Jarowski; C Y Wang; J Halper; H E Broxmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205
  5 in total
  10 in total

1.  Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.

Authors:  Rebekah R White; Wilma E Stanley; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

2.  Serological response of non-human primates to human melanoma disialoganglioside GD3.

Authors:  G M Stuhlmiller; K M Roberson; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Tumor vaccines.

Authors:  J C Bystryn
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

4.  Malignant melanoma arising during pregnancy. A study of 100 patients.

Authors:  C L Slingluff; D S Reintgen; R T Vollmer; H F Seigler
Journal:  Ann Surg       Date:  1990-05       Impact factor: 12.969

5.  Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.

Authors:  C L Slingluff; K R Stidham; W M Ricci; W E Stanley; H F Seigler
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

6.  Sequential combination chemoimmunotherapy for various malignant tumors: clinical and laboratory results.

Authors:  T Akiyoshi; M Kawaguchi; S Miyazaki; F Koba; H Tsuji
Journal:  Jpn J Surg       Date:  1981

7.  Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

9.  In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody.

Authors:  G M Stuhlmiller; D C Sullivan; C E Vervaert; B P Croker; C C Harris; H F Seigler
Journal:  Ann Surg       Date:  1981-11       Impact factor: 12.969

10.  Progress and controversies in developing cancer vaccines.

Authors:  Craig L Slingluff; Daniel E Speiser
Journal:  J Transl Med       Date:  2005-04-29       Impact factor: 5.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.